In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biovitrum buys Swedish Orphan for SEK3.5bn in cash and stock

Executive Summary

Continuing its efforts to transform into solely a specialty pharma company, Sweden's Biovitrum AB will pay SEK3.6bn ($514mm) in cash and stock to buy Swedish Orphan International, a private pan-European company that in-licenses and markets drugs for rare diseases.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Includes Earnout
    • Payment Includes Stock

Related Companies

Advertisement
UsernamePublicRestriction

Register